Trial results for a study investigating acute intermittent hypoxia (AIH) in stroke patients were posted on ClinicalTrials.gov on 2026-04-07, involving 16 participants.

Background

Stroke affects 795,000 people annually in the US, with only a small percentage achieving full recovery. Current therapies focus on strength and endurance, but do not directly target the brain's capacity for reorganization after injury. This study explored acute intermittent hypoxia (AIH), a novel therapy involving brief periods of reduced oxygen levels via a face mask, known to trigger the release of specific substances.

Trial design

This completed study, designated as Phase NA, enrolled 16 participants with Stroke. The trial investigated acute intermittent hypoxia (AIH), where individuals received brief bouts of reduced oxygen levels through a face mask. No comparator arms were detailed in the posted results, and primary outcomes were not specified.

Key results

The trial reported several key measurements for the Hypoxia group:

What this means

The posted results from this small, completed study provide initial safety and functional outcome data for acute intermittent hypoxia in stroke patients. While adverse events were reported, the observed mean changes in functional scales such as NIHSS, Fugl-Meyer Assessment, Modified Ashworth Scale, Grip Strength, and Pinch Strength were generally small, with some indicating a decrease or minimal change, and accompanied by notable standard deviations. Without comparative data or statistical analyses, the clinical significance of these changes remains unclear. This preliminary data may inform the design of future, larger studies.

Source

The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04019522, titled "American Heart Association- Stroke/Hypoxia Study", were posted on 2026-04-07 on clinicaltrials.gov.